HAX’s Zennea Technologies Secures CAD$1 Million for Medical Device to Treat Chronic Snoring

HAX announced on Jan 27th that Zennea Technologies Inc., a Canadian-based medical device company and 2018 graduate of the SOSVs HAX accelerator program, closed a CA$1 million seed round. This funding round saw participation from existing investors SOSV, Saltagen Ventures, and Nimbus Synergies, who were joined by WUTIF and angel investors through the company’s association with Creative Destruction Labs as an alumni venture.

Zennea’s wearable device delivers a therapy to increase tongue patency to reduce airflow restrictions associated with chronic snoring and mild obstructive sleep apnea (OSA). Zennea’s ultimate goal is to reduce the need for surgical interventions. Clinical trials are underway at Calgary Foothills Medical Center and the Tranq Sleep Center at the University of British Columbia.

“Our team has been inspired by the obvious gap in the market for people seeking treatment for their chronic snoring and mild OSA,” said Rachel Chase, founder and CEO of Zennea Technologies. “They’re not able to find a solution that their doctor recommends and alleviates their symptoms without disrupting sleep or resorting to surgery. At Zennea, we aim to offer a new gold standard for treating chronic snoring and mild OSA.”

“Individuals and their partners have suffered from snoring for centuries, often with invasive surgery as their only hope, said Duncan Turner, General Partner at SOSV and Managing Director of HAX. “Zennea surprised us when we first discovered and then invested in the team, and delighted us when we actually tried it.”

Read more about Zennea on the HAX Blog, or on Zennea’s website, Twitter, and Linkedin.